18 results
424B5
KROS
Keros Therapeutics Inc
4 Jan 24
Prospectus supplement for primary offering
4:02pm
is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.
Notice to Prospective Investors in Hong
424B5
KROS
Keros Therapeutics Inc
3 Jan 24
Prospectus supplement for primary offering
4:04pm
supplement is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.
Notice to Prospective
DEF 14A
826ykb5c0
19 Apr 21
Definitive proxy
4:15pm
10-K
yhcpoqyopmlm34t253er
25 Mar 21
Annual report
8:23am
424B4
j38rpa 1uu
13 Nov 20
Prospectus supplement with pricing info
4:02pm
DRS
dufp9muffouzlq1kwu
3 Nov 20
Draft registration statement
12:00am
8-K
EX-99.1
vxqvlo
4 Aug 20
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update
8:32am
424B4
d573fq0ge024bc6q1a77
8 Apr 20
Prospectus supplement with pricing info
4:58pm
S-1
6s96 mlskc
16 Mar 20
IPO registration
4:57pm
DRS/A
f0yguvsmi
27 Feb 20
Draft registration statement (amended)
12:00am
DRS
8848vyxvb6963j64st
21 Jan 20
Draft registration statement
12:00am
- Prev
- 1
- Next